Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with<i>JAK2</i>V617F or calreticulin mutations

Turakhia, Samir; Murugesan, Gurunathan; Cotta, Claudiu V.; Theil, Karl S.

doi:10.1136/jclinpath-2015-203498

Cited by 7 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should be taken into consideration that not only JAK2 or CALR mutations may influence the MPN clinical and laboratory manifestation. In 2016, Turakhia et al showed that thrombocytosis and STAT5 activation in CML patients with thrombocytosis at the time of initial evaluation are not consistently associated with CALR exon 9 or JAK2 V617F mutation.…”

Section: Discussionmentioning

confidence: 99%

Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

Lewandowski

Gniot

Wojtaszewska

et al. 2018

Int J Lab Hematology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

Lewandowski

Gniot

Wojtaszewska

et al. 2018

Int J Lab Hematology

View full text Add to dashboard Cite

show abstract

“…Recently, Turakhia et al24 not only reviewed the blood and bone marrow morphological findings of seven CML-T, four otherwise typical CML and one CML in blast phase but also explored the incidence of JAK2 V617F , CALR mutation and p-STAT5 expression of those patients by RT-PCR and immunohistochemistry (IHC), and results displayed that p-STAT5 was activated in 85.7% (6/7) of CML-T patients. Raised thrombopoietin (TPO) and cmpl (TPO receptor) levels were observed by Karakuş et al25 in CML with thrombocytosis.…”

Section: Discussionmentioning

confidence: 99%

Analysis of clinical characteristics and efficacy of chronic myeloid leukemia onset with extreme thrombocytosis in the era of tyrosine kinase inhibitors

Liu

Fan

et al. 2017

OTT

View full text Add to dashboard Cite

The aim of this study was to investigate the clinical characteristics and efficacy of chronic myeloid leukemia (CML) onset with extreme thrombocytosis. A total of 121 newly diagnosed and untreated CML patients in chronic phase with complete clinical information from the First Hospital of Jilin University, from January 2010 to December 2014 were retrospectively recruited. Based on the platelet (PLT) count, 22 patients were assigned into CML with thrombocytosis (CML-T) group (PLT >1,000×109/L) and 65 patients were classified into CML without extreme thrombocytosis (CML-N) group (PLT ≤1,000×109/L). Fifty-four point five percent of patients in the CML-T group were female, which was higher than that in the CML-N group (27.7%) (P=0.022). Except for gender, there was no significant difference for clinical information of patients between the two groups. For Sokal and Hasford scoring systems, the percentage of patients at high risk in the CML-T group were higher than those in the CML-N group, 95.5% vs 52.3% (P=0.000) and 68.2% vs 41.5% (P=0.031), respectively; however, there was no significant difference for European Treatment and Outcome Study (EUTOS) score system between the two groups (P=0.213). In terms of major molecular response (MMR) rate, the percent of patients with MMR in CML-T group was lower than that in CML-N group at 36 months after tyrosine kinase inhibitor therapy (P=0.037). Up until December 2016, the median of event-free survival was 21 months in the CML-T group, however, that was not reached in the CML-N group (P=0.027). The majority of CML patients with extreme thrombocytosis were females, and compared to patients in the CML-N group, the percentage of high risk patients based on the Sokal and Hasford scoring systems was higher in the CML-T group, and the median event-free survival of patients was shorter.

show abstract

“…Chronic myeloid leukaemia (CML) usually presents with marked leucocytosis, but rare cases may present with an isolated, marked thrombocytosis, defined as a platelet count >1000 × 10 9 /l (Turakhia et al , ).…”

Section: Patient Characteristicsmentioning

confidence: 99%

Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome

et al. 2017

View full text Add to dashboard Cite

Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated withJAK2V617F or calreticulin mutations

Abstract: Detection of BCR-ABL1 is critical in the distinction of ET from CML. Thrombocytosis and STAT5 activation in CML-T are not consistently associated with CALR exon 9 or JAK2 V617F mutation.

Cited by 7 publications

References 22 publications

Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

Analysis of clinical characteristics and efficacy of chronic myeloid leukemia onset with extreme thrombocytosis in the era of tyrosine kinase inhibitors

Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome

Contact Info

Product

Resources

About